Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029088 | 0.81 | PTK2 (0.54) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL20861632 | 0.81 | L3MBTL1 (0.53) | PTK2L3MBTL1CYP1A2GAAPIK3C3 | |
| SCHEMBL23610778 | 0.79 | PTK2 (0.53) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL25118045 | 0.78 | PTK2 (0.51) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL5318470 | 0.78 | PTK2 (0.51) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL31493083 | 0.77 | PTK2 (0.54) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL17606874 | 0.77 | PTK2 (0.54) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL24650720 | 0.77 | PTK2 (0.50) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL24650770 | 0.77 | PTK2 (0.50) | PTK2L3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL31420090 | 0.77 | PTK2 (0.50) | PTK2L3MBTL1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118434727-A | Substituted pyrimidinone derivatives, pharmaceutical compositions and pharmaceutical uses thereof | 上海海雁医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-10717746-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-07-21 | — | — | US | disclosed |
| EP-3539961-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | Astrazeneca AB (SE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717746-B2 | Chemical compounds | CDK9, BCL9, BCL9L | PTK2 358/4885L3MBTL1 1489/4885JAK2 268/4885 |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | PTK2 358/4885L3MBTL1 1489/4885JAK2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.